Patients must have normal organ and marrow function independent of transfusion for at least 7 days prior to screening and independent of growth factor support for at least 14 days prior to screeningXx_NEWLINE_xXEvidence of myeloid engraftment. Use of growth factor supplementation is allowed.Xx_NEWLINE_xXHematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinatorXx_NEWLINE_xXInterleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)Xx_NEWLINE_xXAt least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chairXx_NEWLINE_xXNon-squamous tumors must not be positive for epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutation and anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement (results ascertained in centrally as part of ALCHEMIST-SCREEN protocol)Xx_NEWLINE_xXPatients must not have a known epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) fusion; EGFR/ALK testing is not required prior to registration and is included in the Foundation Medicine Incorporated (FMI) testing for screening/prescreeningXx_NEWLINE_xXREGISTRATION STEP 2-RANDOMIZATION: Patients who are transfusion-dependent and patients receiving growth factor support are eligible; patients must discontinue growth factor support prior to initiation of protocol therapyXx_NEWLINE_xXPatients must have a diagnosis of Philadelphia chromosome negative ALL or Ph chromosome positive ALL by cytogenetics, fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR); patients will be registered to receive treatment in either Cohort 1 (ph-) or Cohort 2 (Ph+ or Ph-like DSMKF) based on these results; diagnostic specimens must be submitted to the site’s local Clinical Laboratory Improvement Amendments (CLIA)-approved cytogenetics laboratory and results of tests (cytogenetics, FISH or PCR) must confirm Ph status prior to registration; if not already known, breakpoint cluster region- abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) status (p190 or p210) must be evaluated in Ph-positive patients by PCR\r\n* For Cohort 2, Ph-like testing is not required specifically for this study; however, to be registered to Cohort 2 under the Ph-like DSMKF criterion, the patient must have a known or presumed activating Ph-like signature and dasatinib-sensitive mutation or kinase fusion, such as: ABL1, ABL2, colony stimulating factor 1 receptor (CSF1R), platelet derived growth factor receptor beta (PDGFRB), platelet derived growth factor receptor alpha (PDGFRA), or fibroblast growth factor receptor (FGFR)s that was otherwise identified as part of normal standard of care; prior to registering any patients with a known or presumed activating Ph-like signature and dasatinib-sensitive mutations or kinase fusions (DSMKF) treating physicians must confirm eligibility with the study chairs via email; the study chairs must respond via email with confirmation of patient eligibility prior to patient registrationXx_NEWLINE_xXAt least 7 days must have elapsed since the completion of therapy with a growth factor; at least 14 days must have elapsed after receiving pegfilgrastimXx_NEWLINE_xXGrowth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment (14 days if pegfilgrastim)Xx_NEWLINE_xXPrior treatment with angiopoietin inhibitors, or inhibitors of tyrosine kinase with immunoglobulin-like and epidermal growth factor (EGF)-like domains (Tie) 1 or Tie2 including, but not limited to, AMG386, CVX-060, XL880, and XL820Xx_NEWLINE_xXHaemopoietic growth factors within 2 weeks prior to receiving study drug.Xx_NEWLINE_xXNo prior anti-epidermal growth factor (EGF) or anti-human epidermal growth factor receptor 2 (HER2) therapyXx_NEWLINE_xXPrevious exposure to pazopanib hydrochloride or a vascular endothelial growth factor receptor (VEGFR) targeted kinase therapy, except for bevacizumab or VEGFR-Trap (Aflibercept)Xx_NEWLINE_xXPatients must be off all colony- forming growth factor(s) for at least 1 week prior to enrollment (i.e. filgrastim, sargramostim or erythropoietin); 2 weeks must have elapsed if patients received long-acting formulationsXx_NEWLINE_xXPatients with nonsquamous NSCLC having functionally significant anaplastic lymphoma kinase (ALK) translocations or epidermal growth factor receptor (EGFR) mutations who have not received prior treatment with ALK or EGFR inhibitor.Xx_NEWLINE_xXPrior treatment with any selective inhibitor (e.g., AZD4547, BGJ398, JNJ-42756493, BAY1179470) of the fibroblast growth factor (FGF)-FGFR pathwayXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of stage IV NSCLC without epidermal growth factor receptor (EGFR)-sensitizing mutation, ROS1 and/or anaplastic lymphoma kinase (ALK) translocationXx_NEWLINE_xXOnly for the 1L Cohort: human epidermal growth factor receptor 2 (HER2)-negative tumors;Xx_NEWLINE_xXTumors lack activating epidermal growth factor receptor (EGFR) mutations or ALK rearrangement (no EGFR or ALK testing is required if a subject has a KRAS mutation or squamous cell histology).Xx_NEWLINE_xXTaken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:Xx_NEWLINE_xXParticipants with known epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapy (including, but not limited to, deletions in exon 19 and exon 21 [L858R] substitution mutations) are excludedXx_NEWLINE_xXAt least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chairXx_NEWLINE_xXPatients must have high PD-L1 expression (Tumor Proportion Score [TPS] ? 50%) as determined by FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. First- or Second-line UROTHELIAL CARCINOMA (atezolizumab only)Xx_NEWLINE_xXANC > 1,500/µl (unsupported by growth factors) andXx_NEWLINE_xXHematopoietic growth factors: patients must be at least 7 days since the completion of therapy with a growth factor prior to registrationXx_NEWLINE_xXHistologically confirmed non-squamous NSCLC; patients with adenocarcinoma must have had epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutational testing; those with an actionable mutations/rearrangements are excludedXx_NEWLINE_xXPatients must be off all colony forming growth factors(s) for at least 1 week prior to registration (filgrastim, sargramostim, erythropoietin) and at least 2 weeks for long-acting formulations (e.g. NEULASTA)Xx_NEWLINE_xXFor Part 2 only: Participants must also have disease with a previously diagnosed activating epidermal growth factor receptor (EGFR) mutation (includes both inhibitor sensitive primary mutations such as Exon 19 deletion and L858R, as well as marketed tyrosine kinase inhibitor [TKI] -resistant mutations such as Exon 20 insertion). Documentation of EGFR mutation eligibility by CLIA-certified laboratory (or equivalent) testing is requiredXx_NEWLINE_xXHematopoietic growth factors: at least 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short acting growth factor; for agents that have known histologic verification of malignancy at original diagnosis or relapse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chairXx_NEWLINE_xXHematologic growth factors are not allowed at Screening or during the first cycle of treatment.Xx_NEWLINE_xXPrior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all adverse events (AEs) have either returned to baseline or stabilizedXx_NEWLINE_xXPatients who have received prior therapy with any irreversible human epidermal growth factor receptor tyrosine kinase inhibitorXx_NEWLINE_xXParticipants may not have received prior therapy with any other Src, platelet-derived growth factor receptors (PDGFR), or fibroblast growth factor receptors (FGFR) inhibitor; prior treatment with an anti-vascular endothelial growth factor receptor (VEGFR) or anti-vascular endothelial growth factor (VEGF) agent is also allowed but only one relapse following a bevacizumab-containing regimen is allowedXx_NEWLINE_xXHave a diagnosis of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer for Parts F and H.Xx_NEWLINE_xXPatients who have received investigational or licensed drugs that target vascular endothelial growth factor [VEGF] or VEGF receptors/pathways (such as bevacizumab, sorafenib, pazopanib, sunitinib, axitinib, cabozantinib, etc.) for the treatment of recurrent cancer are not eligible; exceptions: prior treatment with bevacizumab in the up-front or maintenance setting is allowed, provided the patient had a favorable response to bevacizumab; favorable response is defined as having had a disease free interval of > 6 months following completion of a bevacizumab-containing regimen; if questions, contact the principal investigator (PI)Xx_NEWLINE_xXStudy participants must have had prior epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing; participants with sensitizing mutations in EGFR or ALK rearrangements will be excludedXx_NEWLINE_xXThere is no limit to number of prior treatments; prior bevacizumab is allowed unless it was discontinued due to unacceptable toxicity; prior therapy with tyrosine kinase inhibitors (TKI) targeting vascular endothelial growth factor (VEGF) receptors is allowedXx_NEWLINE_xXAll patients may have had prior surgery, chemotherapy, and radiation therapy; patients with prior vascular endothelial growth factor (VEGF) inhibitor exposure will be placed in the bevacizumab exposed group (groups 2 and 4); prior treatment with Gliadel is permitted for all groupsXx_NEWLINE_xXGrowth factor(s): Must not have received within 1 week of entry onto this study.Xx_NEWLINE_xXHematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor; at least 14 days from the last administration of PEG-ylated GCSF (Neulasta)Xx_NEWLINE_xXUse of hematopoietic growth factors within 4 weeks of treatmentXx_NEWLINE_xXHas a tumor that harbors an epidermal growth factor receptor (EGFR)-sensitizing (activating) mutation or an anaplastic lymphoma kinase (ALK) translocationXx_NEWLINE_xXAbsolute neutrophil count >= 1.5 x 10^9/L within 28 days of treatment initiation and must be independent of hematopoietic growth factor supportXx_NEWLINE_xXPlatelets >= 100 x 10^9/L within 28 days of treatment initiation and must be independent of hematopoietic growth factor supportXx_NEWLINE_xXHemoglobin >= 9 g/dL (transfusion is acceptable to meet this criteria) within 28 days of treatment initiation and must be independent of hematopoietic growth factor supportXx_NEWLINE_xXTotal bilirubin =< 1.5 x ULN within 28 days of treatment initiation and must be independent of hematopoietic growth factor support\r\n* Note: patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (eg, Gilbert syndrome) will be eligible at the discretion of the principal investigatorXx_NEWLINE_xXSubject's central laboratory values must fulfill the following requirements during Screening: Blood product transfusions and hematopoietic growth factors may not be used to meet eligibility criteria. Screening samples should not be collected within 14 days after subject receives a blood product transfusion or growth factors.Xx_NEWLINE_xXAcceptable hematologic status (growth factors cannot be used within the previous 7 days), as specified below:Xx_NEWLINE_xXPlatelet transfusions are acceptable prior to treatment to achieve the above numbers, however growth factors are not allowed within 14 days of registrationXx_NEWLINE_xXHemoglobin < 10.0 g/dL, independent of transfusion or growth factor supportXx_NEWLINE_xXPatients who are planned to receive concurrent growth factor, systemic steroid or other immunosuppressive therapy or cytotoxic agentXx_NEWLINE_xXPatients who are known to have somatic tumor mutations in the following genes, for which targeted agents are available that directly affect the treatment of brain metastasis: Anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), ROS-1 proto-oncogene, and proto-oncogene B-RAFXx_NEWLINE_xXAt least 7 days must have elapsed since the completion of therapy with a growth factor that supports platelet or white cell number or function. At least 14 days must have elapsed after receiving peg-filgrastim.Xx_NEWLINE_xXPlatelets ? 100,000/microliter independent of transfusion and/or growth factors within 3 months prior to randomizationXx_NEWLINE_xXGrowth factors: off all colony forming growth factor(s) for at least 1 week prior to registration (filgrastim, sargramostim, erythropoietin) and at least 2 weeks for long-acting formulationsXx_NEWLINE_xXOff biologic therapies including hematopoietic growth factors >= 1 weekXx_NEWLINE_xXHematologic growth factors are not allowed at Screening or during the first cycle of treatmentXx_NEWLINE_xXHematopoietic growth factors: At least 5 days since the completion of therapy with a growth factor.Xx_NEWLINE_xXPrior chemotherapy, prior epidermal growth factor receptor (EGFR) targeted therapy, or prior radiation therapy for HNSCCXx_NEWLINE_xXWithout transfusion and growth factors within 7 daysXx_NEWLINE_xXPatients with metastatic colorectal cancer who have progressed on, or are ineligible for standard therapy such as fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab and anti-epidermal growth factor receptor (EGFR) antibodies where appropriate, but are suitable candidates for regorafenib treatmentXx_NEWLINE_xXPatients must be off all colony-forming growth factor(s) for at least 1 week prior to registration (e.g. filgrastim, sargramostim, erythropoietin); 2 weeks must have elapsed for long-acting formulationsXx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Patients must be off all colony-forming growth factor(s) for at least 1 week prior to registration (i.e. filgrastim; sargramostim; erythropoietin); 2 weeks must have elapsed for long-acting formulationsXx_NEWLINE_xXGrowth factors: all colony forming growth factor(s) have been discontinued for at least one week prior to enrollment (filgrastim, sargramostim, and erythropoietin); for patients on long acting growth factors, the interval should be two weeksXx_NEWLINE_xX(Part 2 only) Cohort 1: Have histologically or cytologically confirmed diagnosis of Stage IV squamous NSCLC and have not received prior chemotherapy or immunotherapy for metastatic disease and are not known to be PD-L1 positive (known high PD-L1 expression defined as Tumor Proportion Score [TPS] greater than or equal to 50%). Patients with known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) fusion oncogene must have received at least 1 and up to 2 targeted therapies prior to enrollment.Xx_NEWLINE_xXAcceptable hematologic status (without growth factor support or transfusion dependency):Xx_NEWLINE_xXPrior treatment with bevacizumab or other agents targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR)Xx_NEWLINE_xXPrior treatment with an endothelial growth factor receptor (EGFR) inhibitor is allowed if it was a part of prior curative therapy and was completed at least 30 days prior to commencement of study therapyXx_NEWLINE_xXHemoglobin >= 9 g/dl (pre transfusion values used for prognostic factor, can be transfused or use recombinant erythropoietin growth factors but must not have active bleeding)Xx_NEWLINE_xXNo prior epidermal growth factor receptor (EGFR) inhibitor or antiangiogenic agent allowedXx_NEWLINE_xXKnown history of allergy or intolerance which, in the opinion of the investigator, was an unacceptable adverse reaction attributed by the investigator to any prior anti-neoplastic therapy specifically targeting vascular endothelial growth factor or the VEGF receptor – i.e. pazopanib (Votrient), bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent), axitinib (Inlyta), etc.Xx_NEWLINE_xXHematologic growth factors are not allowed at screening or during the first cycle of treatmentXx_NEWLINE_xXTherapy with a growth factor within 7 days of starting study drugXx_NEWLINE_xXPatients who are known to be both V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) and platelet-derived growth factor receptor alpha (PDGRF?) wild type.Xx_NEWLINE_xXPatients who have received neutrophil growth factor support within 14 days of randomization.Xx_NEWLINE_xXPrevious bevacizumab or other vascular endothelial growth factor (VEGF) or anti-angiogenic treatment.Xx_NEWLINE_xXLocally tested, Human Epidermal Growth Factor Receptor 2 (HER2)-expressing BCXx_NEWLINE_xXRadiographic documentation of disease progression while on previous continuous treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)Xx_NEWLINE_xXSubjects with epidermal growth factor (EGFR) activating mutations, EGFR T790M or anaplastic lymphoma kinase gene re-arrangement must have received prior standard of care and have evidence of disease progression.Xx_NEWLINE_xXSTRATUM B: ANC >= to 1000/mm^3 without growth factor support within 7 days of the testXx_NEWLINE_xXSTRATUM C: ANC >= 1,000/mm^3 without growth factor support within 7 days of the testXx_NEWLINE_xXPrior treatment with an hepatocyte growth factor (HGF)/cMet inhibitor such as rilotumumab, crizotinib, MetMAb, or ARQ197Xx_NEWLINE_xXPrior therapy with hydroxyurea, biological or targeted therapy (e.g. flt3 inhibitors, other kinase inhibitors) or hematopoietic growth factors is allowedXx_NEWLINE_xX(* = without ongoing growth factor or transfusion support)Xx_NEWLINE_xXReceived prior fibroblast growth factor receptor (FGFR) inhibitor treatmentXx_NEWLINE_xXPrior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g. FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is permitted in cohort 1 and 2.Xx_NEWLINE_xXFor triple-negative breast cancer, a minimum of 1 prior cytotoxic chemotherapy regimen must have been administered for the indication of metastatic disease.Depending on receptor status, 1 or 2 prior cytotoxic regimens are required prior to enrollment in this trial; hormonal and/or human epidermal growth factor receptor 2 (HER2) -targeted agents may be required.Xx_NEWLINE_xXHematopoietic growth factorsXx_NEWLINE_xXMust have a confirmed Epidermal growth factor receptor amplification in tumor tissueXx_NEWLINE_xXUse of hematopoietic growth factors within 2 weeks prior to initiation of therapyXx_NEWLINE_xXPatients must be off all colony-forming growth factor(s) for at least 1 week prior to registration (filgrastim, sargramostim, erythropoietin) and at least 2 weeks for long-acting formulationsXx_NEWLINE_xXTo be performed within 14 days prior to day 1 of protocol therapy: Absolute neutrophil count (ANC) >= 1,500/mm^3\r\n* NOTE: growth factor support is not permitted to normalize baseline ANC parameters, however subsequent growth factor administration is permitted as standard supportive careXx_NEWLINE_xXPatients with recent (within 15 days preoperatively) history deteriorate kidney function (creatinine serum concentrations > 2.5 mg/dL or epidermal growth factor receptor [eGFR] < 30 mL/kg/min)Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of stage IV NSCLC without epidermal growth factor receptor (EGFR)-sensitizing mutation, ROS1 and/or anaplastic lymphoma kinase (ALK) translocation.Xx_NEWLINE_xXSubject has received colony-stimulating growth factor(s) within 7 days prior to screening (or within 14 days if subject received polyethylene glycol formulations).Xx_NEWLINE_xXMust not have received a long-acting growth factor (eg, Neulasta) within 14 days or a short-acting growth factor within 7 days.Xx_NEWLINE_xXHistologically or cytologically confirmed solid tumor of one of the following types associated with overexpression of Epidermal Growth Factor Receptor (EGFR) or EGFR ligands: Dose Escalation Phase:Xx_NEWLINE_xXAbsolute neutrophil counts of >= 1500/uL (without growth factor support) results within 7 days before study drug administrationXx_NEWLINE_xXPatients must not have received growth factor(s) within 1 week of entry onto this studyXx_NEWLINE_xXHemoglobin > 9 g/dL, without transfusion or hematopoietic growth factorXx_NEWLINE_xXPatients with an active oncogenic driver (e.g., epidermal growth factor [EGFR], activin-receptor-like kinase 1 [ALK1], or the proto-oncogene tyrosine-protein kinase ROS-1) must have progressed on or after a US Food and Drug Administration (FDA)- approved therapy for that aberration (Note: Previous treatment with a tyrosine kinase inhibitor and platinum-based doublets does not exclude the patient.).Xx_NEWLINE_xXPatients must have adequate organ and bone marrow function within 14 days prior to registration, as defined by: platelets >= 100,000/mcl, regardless of transfusion or growth factor supportXx_NEWLINE_xXGrowth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollmentXx_NEWLINE_xXAny prior anti-vascular endothelial growth factor (VEGF) therapies (i.e., sunitinib, sorafenib, pazopanib, axitinib, cabozantinib, bevacizumab, etc.), including in the adjuvant or neoadjuvant settingXx_NEWLINE_xXPlatelet >= 30,000/mm^3 without transfusion or growth factor support for at least 1 weekXx_NEWLINE_xXSubjects must have one of the following: a. somatic mutations in human epidermal growth factor receptor (EGFR, HER2, HER3, and HER4); b. EGFR gene amplification (patients with 3+ results on immunohistochemistry testing for EGFR may be allowed to enroll if gene amplification results are unavailable); c. HER2 gene amplification (patients with 3+ results on immunohistochemistry testing for HER-2 may be allowed to enroll if gene amplification results are unavailable).Xx_NEWLINE_xXAbsolute neutrophil >= 1,000/mcL; transfusion and/or growth factor are permitted within any timeframeXx_NEWLINE_xXHemoglobin > 8.0 g/dL independent of transfusion and growth factor support for at least 7 days prior to screening (except for pegylated G-CSF [pegfilgrastim] and darbepoetin which require at least 14 days prior to screening)Xx_NEWLINE_xXIf the bone marrow evaluation shows heavy infiltration with underlying disease, growth factor support may be administered after screening and prior to the first dose of therapyXx_NEWLINE_xXHematopoietic growth factors: at least 7 days since the completion of therapy with a growth factor that supports platelet, red or white cell number or functionXx_NEWLINE_xXSubjects with known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase receptor (ALK) or ROS1 gene rearrangements must have failed (progressive disease or unacceptable toxicity) at least one prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively. Subject may have received PD-1 or PDL-1 inhibitors and or chemotherapy. There is no limit on lines of prior anti-cancer therapy (a washout period applies for recent anti-cancer treatments).Xx_NEWLINE_xXPrior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g. FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is allowedXx_NEWLINE_xXPlasma vascular endothelial growth factor (VEGF) > 2 x upper limit of normal (ULN)Xx_NEWLINE_xXPrior treatment with nintedanib or any other vascular endothelial growth factor receptor (VEGFR) inhibitorXx_NEWLINE_xXMutational testing of patient samples for KIT and platelet-derived growth factor receptor (PDGFR) mutations; (this will not hold up starting therapy, but will be done for all patients lacking up front mutational testing)Xx_NEWLINE_xXAdministration of myeloid growth factors or platelet transfusion =< 14 days prior to registrationXx_NEWLINE_xXSubjects must have received prior platinum doublet based treatment\r\n* Up to 2 lines of prior systemic therapy for metastatic disease are permitted\r\n* Adjuvant chemotherapy or concurrent chemoradiation for early stage disease does not count as prior therapy unless subject progressed within 6 months of completion of regimen\r\n* Patients with known activating mutations in epidermal growth factor receptor (EGFR), or known translocation in anaplastic lymphoma kinase (ALK) or ROS-1 are eligible provided they have progressed on or were intolerant to Food and Drug Administration (FDA) approved targeted therapyXx_NEWLINE_xXPatients who have received previous investigational agents or biologic therapy, such as tipifarnib, pirfenidone, Peg-intron, sorafenib, or other vascular endothelial growth factor (VEGFR) inhibitors are eligible for enrollmentXx_NEWLINE_xXGrowth factors that support platelet or white cell number or function must not have been administered within the past 7 days and are not permitted while on the studyXx_NEWLINE_xXDiagnosis of metastatic squamous cell carcinoma and/or adenocarcinoma of the esophagus, gastroesophageal junction, or stomach in need of palliative radiotherapy to the primary tumor or a single metastatic site for symptoms such as pain, dysphagia, and/or gastrointestinal bleeding\r\n* Patients with adenocarcinoma histology and known human epidermal growth factor receptor 2 (HER2) overexpressing disease are permitted to participate if the progressed or are intolerant of prior trastuzumab-containing therapyXx_NEWLINE_xXSubjects with histologically or cytologically-confirmed metastatic NSCLC whose disease progressed during/after treatment with at least one platinum-containing chemotherapy regimen; patients whose tumors are known to harbor an exon 19 deletion or exon 21 L858R epidermal growth factor receptor (EGFR) mutation must have progressed on or had intolerance to an EGFR tyrosine kinase inhibitor; patients whose tumors are known to harbor an anaplastic lymphoma kinase (ALK) translocation must have progressed on or had intolerance to an ALK inhibitorXx_NEWLINE_xXPART 2 GROUP 2A INCLUSION CRITERIA: Peripheral ANC >= 1000/mm^3 (1.0 x 10^9/L) without granulocyte growth factor for >= 7 daysXx_NEWLINE_xXPART 2 GROUP 3 INCLUSION CRITERIA: Peripheral ANC >= 1000/mm^3 (1.0 x 10^9/L) without granulocyte growth factor for >= 7 daysXx_NEWLINE_xXAll patients with unhealed wounds or fistulas should not be given vascular endothelial growth factor (VEGF) inhibiting TKIsXx_NEWLINE_xXUROTHELIAL CARCINOMA EXPANSION COHORT: Platelets >= 100,000/mcL without growth factor supportXx_NEWLINE_xXmCRPC EXPANSION COHORT: Platelets >= 100,000/mcL without growth factor supportXx_NEWLINE_xXPrevious treatment with anti-angiogenesis agents including thalidomide, or inhibitors of epidermal growth factor (EGF), platelet derived growth factor (PDGF), or fibroblast growth factors (FGF) receptors within 30 days preceding study entranceXx_NEWLINE_xXBlood transfusion or administration of growth factors within 5 days prior to a blood draw being used to confirm eligibilityXx_NEWLINE_xXPatients must not have received any other treatment for their disease, including hematopoietic growth factors, aside from hydroxyurea for count control, within three weeks of beginning the trial, and should have recovered from all toxicities of prior therapy (to grade 0 or 1)Xx_NEWLINE_xXBone marrow reserve consistent with: hemoglobin >= 9 g/dL values must be obtained without the need for myeloid growth factor support, platelet or PRBC transfusion support within 14 daysXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients with known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations must have been treated on at least one line of molecularly targeted therapy (e.g., erlotinib, crizotinib)Xx_NEWLINE_xXTumor exhibits epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) re-arrangement that qualifies the patient for treatment with a systemic agent targeting these mutationsXx_NEWLINE_xXAt least 14 days must have elapsed after receiving pegfilgrastim and least 7 days must have elapsed since the completion of therapy with a non-pegylated growth factorXx_NEWLINE_xXHave undergone appropriate standard of care treatment options (in the opinion of the treating investigator); patients with NSCLC must have undergone epidermal growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK) testing and have received appropriate initial therapyXx_NEWLINE_xXSubjects must not be receiving growth factors, except for erythropoietinXx_NEWLINE_xXPatients must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) that is advanced/metastatic (stage IIIB/IV) or recurrent (progression after surgery or radiation or chemo-radiation treatment for loco-regional disease); patients with epidermal growth factor (EGFR) mutation, anaplastic lymphoma kinase (ALK) gene rearrangement or ROS1 translocation must have received an approved EGFR, ALK, or reactive oxygen species (ROS)1-directed therapy and have signs of disease progression prior to receiving pembrolizumabXx_NEWLINE_xXPrior therapy with any agent targeting the vascular endothelial growth factor receptor (VEGFR) pathway to include bevacizumab, pazopanib, and other anti-angiogenesis inhibitorsXx_NEWLINE_xXHematopoietic growth factor (At least 14 days from last dose of hematopoietic growth factor prior to first dose of tazemetostat)Xx_NEWLINE_xXCurrent or planned growth factor or transfusion support until after initiation of treatment; if growth factor or transfusion support is provided between screening and start of treatment, the participant will no longer be eligibleXx_NEWLINE_xXPatients may not have received prior treatment affecting the vascular endothelial growth factor (VEGF) pathway (including, but not limited to thalidomide, sunitinib, pazopanib, sorafenib, and nintedanib); bevacizumab used in the upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly diagnosed disease will be allowedXx_NEWLINE_xXTwo or more prior vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) targeted therapies.Xx_NEWLINE_xXSensitizing epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK) and ROS proto-oncogene 1, receptor tyrosine kinase (ROS-1) mutations are either negative or unknownXx_NEWLINE_xXAt least 14 days must have passed after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factorXx_NEWLINE_xXEpidermal growth factor receptor (eGFR) < 50 by Mayo or Cockcroft formulaXx_NEWLINE_xXPatients with lung cancer whose tumors contain activating epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement should be excluded from this study, unless disease has progressed on all available, approved therapies targeting the EGFR mutation or ALK rearrangementXx_NEWLINE_xXAdequate engraftment within 7 days prior to starting study therapy: ANC ? 1.0 x 109/L without daily use of myeloid growth factor; and platelet ? 25 x 109/L without platelet transfusion within 1 weekXx_NEWLINE_xXPrior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g. FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is allowedXx_NEWLINE_xXKnown activating epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocationXx_NEWLINE_xXAt least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor.Xx_NEWLINE_xXGrowth factor(s): must not have received within 2 weeks of entry onto this studyXx_NEWLINE_xXPatients with mCRC must have been previously treated with irinotecan and/or oxaliplatin and/or vascular endothelial growth factor (VEGF)/epidermal growth factor receptor (EGFR) therapy or intolerant to these agentsXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with any actionable mutation or translocation in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or c-ros oncogene 1 (ROS1)Xx_NEWLINE_xXPatients with epidermal growth factor receptor (EGFR) or transforming fusion gene EML4-ALK variant 4 (EML4-ALK) mutationsXx_NEWLINE_xXAbsolute neutrophil count >= 1,200/mcL (without growth factor support)Xx_NEWLINE_xXHistologically confirmed unresectable solid tumor malignancy with at least 1 measurable lesion in dose escalation; in the expansion phase, eligibility limited to metastatic triple negative breast cancer that has received prior taxane and anthracycline therapy; metastatic non-small cell lung cancer (NSCLC) that is not anaplastic lymphoma kinase positive (ALK+) and does not have a epidermal growth factor receptor (EGFR) sensitizing mutation; and metastatic gastric cancerXx_NEWLINE_xXPatients must have activating genomic alterations in FGFR (mutations, fusions or amplifications [> 6 copies]) or activating genomic alterations in mast/stem cell growth factor receptor kit (KIT), platelet-derived growth factor receptor alpha (PDGFR alpha), ret proto-oncogene (RET), ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) and fms-related tyrosine kinase 3 (FLT3) by any validated Clinical Laboratory Improvement Amendments (CLIA)-certified molecular testing (fluorescent in situ hybridization [FISH], polymerase chain reaction [PCR] or sequencing data are acceptable); CLIA validated results from other institutions; diagnostic labs (e.g. foundation medicine) are acceptableXx_NEWLINE_xXPatients with known ponatinib-resistant gene alterations\r\n* Platelet derived growth factor receptor, alpha polypeptide (PDGFRA) D842V mutation\r\n* Mast/stem cell growth factor receptor Kit (cKIT) D816V mutation\r\n* FLT3 D835V/Y/H/F or Y842C mutations\r\n* Fibroblast growth factor receptor 3 (FGFR3) K652E mutationXx_NEWLINE_xXHistologically confirmed diagnosis of advanced (metastatic or unresectable) non-small cell lung cancer (NSCLC) with mutations, rearrangement and fusion involving RET oncogene, or abnormalities in the pazopanib target genes defined as vascular endothelial growth factor receptors 1-3 (VEGFR1-3), platelet-derived growth factor receptor-alpha (PDGFRA), or platelet-derived growth factor receptor-beta (PDGFRB), or tumor protein p53 (TP53) with abnormalities including deletion, insertion, early stop codon, and/or nonsynonymous mutations with functional consequences; Clinical Laboratory Improvement Act (CLIA) certified lab testing for pazopanib target genes using cell free deoxyribonucleic acid (DNA) from peripheral blood and/or assays performed on tumor tissues are acceptableXx_NEWLINE_xXValues must be obtained without need for myeloid growth factor or platelet transfusion support within 14 days of registration; however, erythrocyte growth factor is allowed as per published American Society of Clinical Oncology (ASCO) guidelinesXx_NEWLINE_xXCOHORT II: Core tissue must have human epidermal growth factor receptor 2 (HER 2) testingXx_NEWLINE_xXUse of Avastin or another vascular endothelial growth-factor (VEG-F) inhibitor prior to progression is not permittedXx_NEWLINE_xXMust not have received any hematopoietic growth factors within 7 days/Xx_NEWLINE_xXPlatelets > 50 K without growth factor or transfusion support for a week at leastXx_NEWLINE_xXHematopoietic growth factors: At least 5 days since the completion of therapy with a growth factor.Xx_NEWLINE_xXPatients must have tumor tissue available for submission that is sufficient to complete c-MET fluorescence in situ hybridization (FISH) studies as well as routine molecular profiling at the University of Pittsburgh Medical Center (UPMC); patients must agree to submission of these specimens\r\n* c-MET amplification will be determined by FISH ratio (c-MET/chromosome 7 centromere probe [CEP7]) > 2.0, based on testing of the primary tumor and/or site of metastatic disease\r\n* Patients’ tumors must undergo testing for epidermal growth factor receptor (EGFR) exon 19 deletion, EGFR exon 21 leucine substitution at position 858 (L858R) substitution, and anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangements; if positive, patients must have been treated with an appropriate tyrosine-kinase inhibitor (TKI) prior to enrolling to the studyXx_NEWLINE_xXPrior exposure to the investigational agent or anti-c-Met, anti-hepatocyte growth factor (HGF) or anti-vascular endothelial growth factor (VEGF) directed therapy within six months prior to study entryXx_NEWLINE_xXPreviously untreated AML patients, except those who have received prior therapy with hydroxyurea, single agent chemotherapy (e.g. decitabine), hematopoietic growth factors, biological or targeted therapies are allowedXx_NEWLINE_xXPatients must not have received myeloid growth factors within 2 weeks before mobilization attempt on this studyXx_NEWLINE_xXPatients who have received growth factors within 14 days prior to initiation of dosing of CFI-400945 fumarate.Xx_NEWLINE_xXGreater than two cycles of bevacizumab or any prior therapy with an inhibitor of vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)Xx_NEWLINE_xXPrior receipt of bevacizumab or other vascular endothelial growth factor (VEGF) negative (-) or VEGF receptor-targeted agentsXx_NEWLINE_xXPatients must not be receiving growth factorsXx_NEWLINE_xXHuman epidermal growth factor receptor 2 (HER2)-neu positiveXx_NEWLINE_xXThe use of the following within 30 days before treatment:\r\n* Immunosuppressive drugs\r\n* Systemic glucocorticoids\r\n* Hematopoietic growth factors\r\n* Experimental therapyXx_NEWLINE_xXThe use of the following within 14 days before treatment:\r\n* Chemotherapy\r\n* Radiation therapy\r\n* Immunosuppressive drugs\r\n* Systemic glucocorticoids\r\n* Hematopoietic growth factors\r\n* Experimental therapyXx_NEWLINE_xXGrowth factors that support platelet or white cell number or function must not have been administered within the past 28 daysXx_NEWLINE_xXTreatment with any of the following anti-cancer therapies: \r\n* Radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR\r\n* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib \r\n* Any prior treatment with pazopanib or vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)-targeting agents (eg. sorafenib, sunitinib, and bevacizumab) \r\n* Any prior treatment with gemcitabineXx_NEWLINE_xXPatients may not have previously failed treatment with a vascular endothelial growth factor (VEGF) inhibitorXx_NEWLINE_xXPHASE II: Patients must not have received prior therapy with sorafenib, everolimus, or related drugs such as tyrosine kinase inhibitors, vascular endothelial growth factor (VEGF) inhibitors (except bevacizumab), or mechanistic target of rapamycin (mTOR) inhibitorsXx_NEWLINE_xXAbsolute neutrophil count >= 1.0 K/mcL, without use of growth factor support for 1 weekXx_NEWLINE_xXNOTE: white blood count and platelet count criteria must be met without any transfusion or growth factor supportXx_NEWLINE_xXAdequate hematologic function independent of growth factor support for at least 7 days prior to screening and randomization, with the exception of pegylated G-CSF (pegfilgrastim) and darbepoetin which cannot be administered within 14 days of screeningXx_NEWLINE_xXHematopoietic growth factors: ?14 days after the last dose of a long-acting growth factor (eg, Neulasta) or 7 days for a short-acting growth factor. For agents that have known adverse events (AEs) occurring beyond 7 days after administration, this period must be extended beyond the time during which AEs are known to occur.Xx_NEWLINE_xXInterleukins, interferons, and cytokines (other than hematopoietic growth factors): ?21 days after the completion of interleukins, interferons, or cytokines (other than hematopoietic growth factors)Xx_NEWLINE_xXPart 2: Has a histologically-confirmed adenocarcinoma originating from the colon or rectum (Stage 4 American Joint Committee on Cancer [AJCC] 7th edition). Appendiceal cancer is included. AND Has experienced disease progression or was intolerant to at least 1 and up to 5 systemic chemotherapy regimen(s) for metastatic CRC that must have included fluroropyrimidines and irinotecan or oxaliplatin, ± anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR)(if indicated by RAS mutational status).Xx_NEWLINE_xXReceiving hematopoietic growth factorsXx_NEWLINE_xXAbsence of an activating mutation (Exon 19 deletion or Exon 21 L858R mutation) in the epidermal growth factor receptor (EGFR) in the pre-treatment biopsy of the tumor. Patients with activating EGFR mutations are eligible if they have progressed following treatment with erlotinib. A pretreatment tumor biopsy must be available for analysis. If a biopsy has not been performed prior to entry, then a biopsy will be required.Xx_NEWLINE_xXCurrently being treated with hematopoietic growth factors other than erythropoietin (EPO). Treatment with hematopoietic growth factors may be started during the study with development, or worsening, of cytopeniaXx_NEWLINE_xXReceived growth factor support or transfusions to achieve hematology entry criteria (platelets, hemoglobin, absolute neutrophil count)Xx_NEWLINE_xXTumors must demonstrate epidermal growth factor receptor (EGFR) amplification.Xx_NEWLINE_xXHas confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), c-ros oncogene 1- (ROS1-), or B isoform of rapidly accelerated fibrosarcoma- (B-Raf-) directed therapy is not indicated as primary therapy (documentation of absence of tumor activating EGFR or B-Raf mutations AND absence of ALK or ROS1 gene rearrangements)Xx_NEWLINE_xXHas received previous treatment with another agent targeting endothelial growth factor (VEGF) or the VEGF receptorXx_NEWLINE_xXPatients with tumors tested positive for Epidermal growth factor receptor (EGFR) gene mutations, Anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene receptor tyrosine kinase(ROS1) fusionsXx_NEWLINE_xXLife expectancy greater or equal to 3 months, as determined by the investigator -Patients must have progressed on the standard therapy, including platinum based - chemotherapy. Patients with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS-1 mutations must have progressed on standard treatment options including EGFR, ALK, or ROS-1-directed therapies.Xx_NEWLINE_xXEpidermal growth factor receptor (EGFR) mutant and/or anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearranged tumorXx_NEWLINE_xXAll cytokines or hematopoietic growth factors must be discontinued a minimum of 7 days prior to the start of vorinostat on this protocolXx_NEWLINE_xXANC >= 750/uL (no hematopoietic growth factors within 7 days of the start date for vorinostat on this protocol)Xx_NEWLINE_xXTreatment with a vascular endothelial growth factor (VEGF) inhibitor within the last 6 weeksXx_NEWLINE_xXPlatelets >= 100,000/mm^3 (without transfusion or growth factor support)Xx_NEWLINE_xXHave mCRC that has been treated with currently approved standard therapies, including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) therapy, and, if Kirsten rat sarcoma viral oncogene homolog (KRAS) wild type, an anti-epidermal growth factor receptor (EGFR) therapyXx_NEWLINE_xXPatients must be off all colony- forming growth factor(s) for at least 1 week prior to enrollment (i.e., filgrastim, sargramostim or erythropoietin); 2 weeks must have elapsed if patients received polyethylene glycol (PEG) formulationsXx_NEWLINE_xXPreviously untreated with HMAs (prior therapy with transfusions, hematopoietic growth factors, or immunosuppressive therapy is allowed).Xx_NEWLINE_xXConcomitant medication restrictions\r\n* Growth factor(s): growth factors that support platelet or white cell number or function must not have been administered within 7 days prior to enrollment (14 days if Neulasta)\r\n* Corticosteroids: patients requiring corticosteroids should not be on a chronic dose; patients should be off steroid for at least 14 days prior to immunotherapy (IT) and they should not receive steroids during protocol treatment\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXTREATMENT: Patients with non-small cell lung cancer (NSCLC) must have previously been tested for the presence of epidermal growth factor receptor (EGFR) mutations, and, if detected, should have received and progressed on EGFR tyrosine kinase inhibitor (TKI) therapyXx_NEWLINE_xXPatient must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for epidermal growth factor receptor (EGFR) analysis and for oropharyngeal cancer patients, human papilloma virus (HPV) analysisXx_NEWLINE_xXSubjects must not be receiving growth factors, except for erythropoietinXx_NEWLINE_xXGrowth factors:\r\n* Patients must not have received growth factors for 7 days prior to CPX-351\r\n* Patients must not have received pegfilgrastim for 14 days prior to CPX-351Xx_NEWLINE_xXPatients must have newly diagnosed histologically or cytologically confirmed NSCLC, staged IIIB or IV, for which they have not received first-line cytotoxic chemotherapy (first-line epidermal growth factor receptor [EGFR] inhibitors or anaplastic lymphoma kinase [ALK] inhibitors are allowed given disease progression)Xx_NEWLINE_xXRenal cell patients must have had at least one prior vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)Xx_NEWLINE_xXPrior treatment with bevacizumab or other anti-vascular endothelial growth factor (VEGF) drugsXx_NEWLINE_xXPrior treatment with tyrosine-kinase inhibitors targeting VEGF, platelet-derived growth factor, fibroblast growth factor, tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 (TIE-2), or angiopoietin (or their receptors)Xx_NEWLINE_xXAll cytokines or hematopoietic growth factors must be discontinued a minimum of 7 days prior to protocol therapyXx_NEWLINE_xXIf present, primary disease in the prostate must be stable for > 6 months (defined as no growth > 5 mm)Xx_NEWLINE_xXPrevious exposure to vascular endothelial growth factor (VEGF) inhibitor(s)Xx_NEWLINE_xXSubjects should have received at least one prior platinum based chemotherapy and an immune checkpoint targeted agent; subjects with epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-translocated non-small cell lung cancer (NSCLC) should have received Food and Drug Administration (FDA)-approved targeted therapies as appropriateXx_NEWLINE_xXUp to 3 lines of prior vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR) targeted therapy are permitted; any prior therapy should have been completed >= 2 weeks prior to start of study therapyXx_NEWLINE_xXAll biologic agents including hematopoietic growth factors must have been stopped at least 1 week prior to treatment on the studyXx_NEWLINE_xXPatients who are found to have a cancer positive for the marker human epidermal growth factor receptor 2 (HER-2)/neu (Note: this exclusion criterion applies only to patients at the New York University [NYU] Tisch and Bellevue sites where there is currently a protocol open and available for patients who are HER-2/neu positive; this exclusion criterion does not apply to patients at the South Africa site)Xx_NEWLINE_xXPatients may have received bevacizumab, vascular endothelial growth factor (VEGF)-Trap, or other VEGF blocking tyrosine kinase inhibitors, but may not have received axitinibXx_NEWLINE_xXHematopoietic growth factors: at least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chairXx_NEWLINE_xXFor Phase IB Extension Only:\r\n* Either or both of the following:\r\n** A tumor which harbors an activating epidermal growth factor receptor (EGFR)-mutation\r\n** History of objective response, or stable disease for at least 6 months, after treatment with erlotinib, afatinib, or gefitinib\r\n* Either or both of the following:\r\n** Progression or recurrence of disease after receiving prior continuous gefitinib, afatinib, or erlotinib\r\n** A tumor known to harbor a de novo T790M mutation, which is known to confer EGFR TKI resistance\r\n* Participants are allowed to have received systemic chemotherapy or investigational therapy in the intervening period prior to trial enrollmentXx_NEWLINE_xXPatients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer or ovarian cancer should have received at least two lines of systemic therapy in the advanced settingXx_NEWLINE_xXPatients with prior anti-epidermal growth-factor receptor antibody therapy (antibody or small molecule)Xx_NEWLINE_xXPrior therapy with any agent targeting the HER2 pathway or human epidermal growth factor receptor 1 (HER1) (epidermal growth factor receptor [EGFR]) pathwayXx_NEWLINE_xXPrior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all adverse events have either returned to baseline or stabilizedXx_NEWLINE_xXPrior therapy that specifically and directly targets the epidermal growth factor receptor (EGFR) pathwayXx_NEWLINE_xXAt least 7 days since the completion of therapy with a growth factorXx_NEWLINE_xXPatients with prior anti-epidermal growth-factor receptor antibody therapy (antibody or small molecule)Xx_NEWLINE_xXPatients who have received prior therapy with trastuzumab or any other anti-epidermal growth factor type II receptor antibodyXx_NEWLINE_xXPrior use of raf-kinase inhibitors (sorafenib), vascular endothelial growth factor (VEGF) inhibitors, mitogen-activated protein kinase (MAPK)/extracellular-signal-related kinase (ERK) kinase (MEK) inhibitors, or farnesyl transferase inhibitorsXx_NEWLINE_xXHematopoietic growth factor (At least 14 days from last dose of hematopoietic growth factor prior to first dose of tazemetostat)Xx_NEWLINE_xXPrior systemic treatment in the metastatic setting with Vascular epithelial growth factor(VEGF) or VEGF receptor targeted therapyXx_NEWLINE_xXEvidence of myeloid engraftment (eg, absolute neutrophil count ? 0.5 × 10^9/L for 3 consecutive days if ablative therapy was previously used). Use of growth factor supplementation is allowed.Xx_NEWLINE_xXPrevious anti-angiogenics or anti-vascular endothelial growth factor within 12 months of registrationXx_NEWLINE_xXTumors with epidermal growth factor receptor mutation positive or anaplastic lymphoma kinase fusion oncogene positive treated with a tyrosine kinase inhibitor are permitted; however, subjects should have progressed on or be intolerant to the targeted therapy.Xx_NEWLINE_xXFor the phase II portion, patients must have histologically and/or cytologically confirmed metastatic colorectal carcinoma that has progressed on, is intolerant of, or is inappropriate for all standard therapies; subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan and bevacizumab or have contraindication to such treatment; prior epithelial growth factor receptor (EGFR)-targeting agent (or contraindication to these drugs) is required for subjects with K-Ras wildtype tumorsXx_NEWLINE_xXTumor shown to be human epidermal growth factor 2 plus (HER2+)Xx_NEWLINE_xXANC ? 750 cells/?L or ? 500 cells/?L in subjects with documented bone marrow involvement, and independent of growth factor support 7 days before assessment.Xx_NEWLINE_xXANC ? 750 cells/?L, or ? 500 cells/?L in subjects with documented bone marrow involvement, and independent of growth factor support 7 days before assessment.Xx_NEWLINE_xXNon-small cell lung cancer (NSCLC)\r\n* Metastatic or locally advanced disease that progressed after at least one prior therapy \r\n* Note: patients who have actionable molecular targets (e.g., epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], c-ros oncogene 1[ROS1] mutations) must have received (when indicated) prior appropriate targeted therapy using Food and Drug Administration (FDA)-approved agentsXx_NEWLINE_xXPrior or current use of systemic anti-vascular endothelial growth factor (VEGF) inhibitors, cytokines or mammalian target of rapamycin (mTOR) inhibitors (e.g. interferon, interleukin 2)Xx_NEWLINE_xXPrior treatment with anti-epidermal growth factor receptor (EGFR) therapy (either panitumumab or cetuximab)Xx_NEWLINE_xXPrior systemic regimens must include previously approved therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy (if no contraindication); and if negative for KRAS, NRAS, and BRAF mutations and no contraindication, an anti-epidermal growth factor receptor (EGFR) therapy; and progressed after the last administration of approved therapy.Xx_NEWLINE_xXHas confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated.Xx_NEWLINE_xXHematopoietic growth factor At least 14 daysXx_NEWLINE_xXHas received prior systemic anti-cancer therapy for RCC with vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFR) or mechanistic target of rapamycin (mTOR) targeting agents.Xx_NEWLINE_xXTreatment with a long-acting hematopoietic growth factor within 2 weeks prior to initiation of study drug or a short-acting hematopoietic growth factor within 1 week prior to initiation of study drugXx_NEWLINE_xXPrior progression following a fluoropyrimidine-based therapy and progression following or intolerance to irinotecan and oxaliplatin, as well as anti-epidermal growth factor receptor (EGFR) therapy (e.g., panitumumab or cetuximab) for rat sarcoma viral oncogene homolog (RAS) wild-type patientsXx_NEWLINE_xXAbsence of known epidermal growth factor receptor (EGFR) mutationXx_NEWLINE_xXHuman epidermal growth factor receptor 2 (HER2)-negative tumor (primary tumor or metastatic lesion)Xx_NEWLINE_xXPatients must be off all non-transfusion therapy for MDS for 28 days prior to initiation of study treatment, including all types of growth factors; patients may receive hydrocortisone prophylactically to prevent transfusion reactionsXx_NEWLINE_xXAny patient requiring chronic maintenance of white blood cell counts or granulocyte counts through the use of growth factor support (e.g. Neulasta, Neupogen)Xx_NEWLINE_xXHematopoietic growth factor; at least 14 days from last doseXx_NEWLINE_xXANC ?1000/mm3 (?1.0 × 109/L) without growth factor support for 14 daysXx_NEWLINE_xXUse of any vascular endothelial growth factor (VEGF) targeted therapy or previous use of regorafenib.Xx_NEWLINE_xXPatients receiving erythropoiesis-stimulating agents or other hematopoietic growth factors.Xx_NEWLINE_xXHuman Epidermal Growth Factor Receptor 2 (HER2)-positive gastric cancerXx_NEWLINE_xXHas received any previous systemic therapy targeting vascular endothelial growth factor (VEGF) or VEGF receptor, or programmed death (PD) 1 or PD-ligand 1/2 signaling pathways.Xx_NEWLINE_xXHematologic growth factors are not allowed at screening or during the first cycle of phase 1a or 1b.Xx_NEWLINE_xXLaboratory results within 7 days prior to MRZ administration (transfusions and/or growth factor support may not be used to meet this criteria):Xx_NEWLINE_xXPrior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all adverse events have either returned to baseline or stabilizedXx_NEWLINE_xXParticipants with epidermal growth factor receptor (EGFR) sensitizing mutations and anaplastic lymphoma kinase (ALK) rearrangementsXx_NEWLINE_xXPrior therapy with monoclonal antibodies or small molecule inhibitors against Vascular endothelial growth factor (VEGF) or VEGF receptors, including Avastin® or Avastin® biosimilarXx_NEWLINE_xXhave received prior second-line treatment with oxaliplatin and/or irinotecan, and no other licensed/standard-of-care therapies are available. If the participant has RAS wild type colorectal cancer, he or she also must have received prior treatment with an epidermal growth factor receptor monoclonal antibodyXx_NEWLINE_xXEvidence of myeloid engraftment. Use of growth factor supplementation is allowed.Xx_NEWLINE_xXAdequate hematologic function without growth factor or transfusion supportXx_NEWLINE_xXDiscretionary use of growth factors allowedXx_NEWLINE_xXPatients with the factor interacting with poly(A) polymerase alpha (PAPOLA) and cleavage and polyadenylation specific factor 1 (CPSF1) (FIP1L1)-platelet-derived growth factor receptor, alpha polypeptide (PDGFRalpha) fusion even with resistance to imatinib (such patients are no longer defined as systemic mastocytosis by the WHO)Xx_NEWLINE_xXPrior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g. FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is allowedXx_NEWLINE_xXHave received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), or VEGF receptor.Xx_NEWLINE_xXParticipants with human epidermal growth factor receptor 2 (HER2)-positive status.Xx_NEWLINE_xXAdministration of myeloid growth factors or platelet transfusion within 14 days prior to the first dose of study treatmentXx_NEWLINE_xXInclusion criteria:\n\n        Adult patients aged >=18 years with histologically or cytologically confirmed advanced\n        nonsquamous non-small cell lung cancer (nsNSCLC). Mixed tumors should be categorized\n        according to the predominant histology.\n\n        Note: NSCLC should be predominantly nonsquamous. Recurrent or metastatic disease (Stage IV)\n        with an indication for therapy with paclitaxel + carboplatin + Avastin®.\n\n        Patients harboring tumors with unknown or without activating epidermal growth factor\n        receptor (EGFR) / anaplastic lymphoma receptor tyrosine kinase (ALK) mutation maybe\n        included provided chemotherapy is standard of care. At least one measurable lesion\n        according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on independent\n        central review.\n\n        Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.\n\n        Adequate hepatic, renal, and bone marrow function:\n\n        Life expectancy > 6 months based on clinical judgment. Further inclusion criteria apply.\n\n        Exclusion criteria:\n\n        Prior therapy with monoclonal antibodies or small molecule inhibitors against Vascular\n        Endothelial Growth Factor (VEGF) or VEGF receptors, including Avastin®.\n\n        Prior systemic therapy for metastatic disease. Prior systemic anticancer therapy or\n        radiotherapy for locally advanced nsNSCLC if completed <12 months prior to Screening.\n\n        Previous malignancy other than NSCLC in the last 5 years except for basal cell cancer of\n        the skin or pre-invasive cancer of the cervix.\n\n        Symptomatic brain metastasis. Diagnosis of small cell carcinoma of the lung, squamous cell\n        carcinoma of the lung, NSCLC not specified (NS) or NSCLC not otherwise specified(NOS).\n\n        Any unresolved toxicity > Common Toxicity Criteria Grade 1 (except alopecia) from previous\n        anticancer therapy (including radiotherapy).\n\n        History or evidence of inherited bleeding diathesis or coagulopathy with the risk of\n        bleeding. Thrombotic or hemorrhagic event =< 6 months prior to Screening. Further exclusion\n        criteria apply.Xx_NEWLINE_xXPrior therapy with agents targeting Insulin Growth Factor (IGF) and/or Insulin Growth Factor Receptor (IGFR) pathway.Xx_NEWLINE_xXHistological or cytological diagnosis of Stage IV NSCLC lacking epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) translocation, and received no prior systemic chemotherapy treatment for their metastatic NSCLCXx_NEWLINE_xXDose escalation subjects: Epidermal Growth Factor Receptor (EGFR) activating mutation by local testing: exon 18 G719X, exon 19 deletion, exon 21 L861Q, exon 21 L858R or exon 20 insertion; and received prior treatment with EGFR Tyrosine Kinase Inhibitor (TKI)Xx_NEWLINE_xXSubjects with non-squamous histology must be tested for Epithelial Growth Factor Receptor (EGFR) mutations (including, but not limited to, deletions in exon 19 and exon 21 [L858R] substitution) and Anaplastic Lymphoma Kinase (ALK) rearrangement if tests have not been previously performed. Subjects with progressive disease during or after EGFR or ALK tyrosine kinase inhibitor (TKI) regimens are eligible. Subjects are eligible if genetic test results are indeterminate or if no tumor tissue is available or accessible for testing as long as they have received one prior systemic therapyXx_NEWLINE_xXPrior therapy with growth factor support, lenalidomide, 5-azacytidine, decitabine or other investigational agents are allowed; a four week wash out period will be required before receiving study medicationXx_NEWLINE_xXPatients who have received hematopoietic growth factor support within 14 days of day 1 of SGN-35Xx_NEWLINE_xXPatients must not have received long-acting myeloid growth factors (e.g., Neulasta) within 14 days of entry on this study; seven days must have elapsed since administration of a short acting myeloid growth factorXx_NEWLINE_xXPrior treatment with other small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR) within =< 2 years of study enrollmentXx_NEWLINE_xXParticipant has a known sensitivity to agents of similar biologic composition as ramucirumab or other agents that specifically target vascular endothelial growth factor (VEGF)Xx_NEWLINE_xXDocumentation of human epidermal growth factor receptor 2 (HER2)-negative tumor.Xx_NEWLINE_xX(* = without ongoing growth factor or transfusion support)Xx_NEWLINE_xXThe patient must have a pathologically confirmed (by histology, cytology, or immunohistology) diagnosis of TNBC (a cancer that does not meaningfully express the estrogen or progesterone hormone receptors or overexpress the human epidermal growth factor receptor 2 tyrosine kinase), which is currently advanced/metastatic disease.Xx_NEWLINE_xXPatients with NSCLC and known anaplastic lymphoma kinase (ALK) translocations or epidermal growth factor receptor (EGFR) mutations who have not received prior treatment with ALK or EGFR inhibitor.Xx_NEWLINE_xXSubjects with characterized Epidermal Growth Factor Receptor (EGFR) activating mutations that predict sensitivity to anti-EGFR-therapy, including, but not limited to exon 19 deletions and exon 21 alterationsXx_NEWLINE_xXGrowth factor or cytokine supportXx_NEWLINE_xXWithin 72 h of initiating study treatment: Platelets >= 100,000/mm^3; Note: transfusions of blood and blood products as well as growth factor support are prohibited within 14 days prior to the first dose of study treatmentXx_NEWLINE_xXSubjects must have histologically confirmed, unresectable, locally advanced or metastatic pleural or peritoneal predominantly (>50% of tumor component) epithelial mesothelioma or nonsquamous non-small-cell lung cancer (NSCLC). Both chemotherapy-naive and previously treated subjects will be eligible; however, newly diagnosed NSCLC subjects eligible for FDA-approved therapies should have received the same before enrollment (e.g. subjects with epidermal growth factor receptor [EGFR]-mutated and anaplastic lymphoma kinase [ALK]-translocated NSCLC should have received FDA-approved targeted therapies).Xx_NEWLINE_xXNo prior treatment with BIBF 1120 or any other vascular endothelial growth factor receptor (VEGFR) inhibitor, not including bevacizumabXx_NEWLINE_xXParticipants with non-squamous histology has known or unknown sensitizing epidermal growth factor receptor (EGFR) and/or anaplastic lymphoma kinase positive (ALK) mutation. Note: Participants with squamous histology and unknown EGFR and ALK mutational status are eligible.Xx_NEWLINE_xXPatients who are Human epidermal growth factor 2 +(HER2+) as defined by American Society of Clinical Oncology and College of American Pathologists (ASCO CAP) guidelines must have failed all prior therapy known to confer clinical benefitXx_NEWLINE_xXThe participant received previous treatment with agents targeting the vascular endothelial growth factor (VEGF)/VEGF receptor 2 signaling pathway.Xx_NEWLINE_xXPatients must be off all colony-forming growth factor(s) for at least 1 week prior to enrollment (i.e. filgrastim, sargramostim); two weeks must have elapsed if patients received polyethylene glycol (PEG) formulationsXx_NEWLINE_xXELIGIBILITY FOR TREATMENT ON ARM 1: NSCLC patients with a mutation in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) must have demonstrated progression or intolerance to at least one of the corresponding targeted therapies (for example erlotinib or crizotinib)Xx_NEWLINE_xXParticipants may not have had prior use of poly ADP ribose polymerase (PARP) inhibitors; patients may not have received prior treatment affecting the vascular endothelial growth factor (VEGF) pathway in the recurrent setting, including but not limited to thalidomide, bevacizumab, sunitinib, or sorafenibXx_NEWLINE_xXHas received anti-angiogenic or anti-vascular endothelial growth factor (VEGF) targeted agents (e.g. bevacizumab, cediranib, aflibercept, vandetanib, XL-184, sunitinib, etc.)Xx_NEWLINE_xXAdequate marrow function independent of growth factor or transfusion support within 2 weeks of screening as per protocol, unless cytopenia is due to marrow involvement of CLLXx_NEWLINE_xXBefore starting study treatment, all patients must have recovered from toxic effects of prior therapies; at least 2 weeks must have elapsed since any prior signaling pathway modulators, (e.g., epidermal growth factor receptor [EGFR], fibroblast growth factor receptor [FGFR], or other tyrosine kinase inhibitors), at least 3 weeks must have elapsed since temozolomide, 4 weeks must have elapsed since carboplatin or cisplatin, and at least 6 weeks from nitrosoureas (e.g., carmustine [BCNU], lomustine [CCNU]); in general, at least 4 weeks must have elapsed from any other anticancer therapy; prior anticancer therapies not encompassed above will be permitted at the discretion of the investigatorXx_NEWLINE_xXHuman epidermal growth factor receptor 2 (HER-2) positive esophagogastric cancer; patients with unknown HER2 status are permittedXx_NEWLINE_xXPrior treatment with vascular endothelial growth factor receptor (VEGFR) inhibitorXx_NEWLINE_xXAdministration of myeloid growth factors or platelet transfusion within 14 days prior to the first dose of study treatmentXx_NEWLINE_xXHematologic(These values must be independent of growth factor support and stable for at least one week post transfusion)Xx_NEWLINE_xXSerum bilirubin <=1.25 x upper limit of normal (ULN)( These values must be independent of growth factor support and stable for at least one week post transfusion)Xx_NEWLINE_xXPatients must have normal organ and marrow function, independent of transfusion or growth factor support within 14 days before enrollment; patients should not receive growth factors or transfusions for at least 7 days prior to the first dose of study drug, with the exception of pegylated GCSF (pegfilgrastim) and darbepoetin, which require at least 14 days prior to screening and enrollmentXx_NEWLINE_xXPrior treatment in the adjuvant or metastatic setting with any of the following:\r\n* Agents disrupting VEGF activity or targeting vascular endothelial growth factor receptor (VEGFR);\r\n* Ipilimumab;\r\n* Or taxane based chemotherapy regimens (including paclitaxel, docetaxel, cabazitaxel or nab-paclitaxel)Xx_NEWLINE_xXPatients who have received prior bevacizumab (or any other vascular endothelial growth factor [VEGF] targeted agent) or prior poly ADP ribose polymerase (PARP) inhibitorXx_NEWLINE_xXPatients must not have been treated with any vascular endothelial growth factor (VEGF) inhibitorsXx_NEWLINE_xXSubject has non-squamous NSCLC, or a known Epidermal Growth Factor Receptor (EGFR) mutation of exon 19 deletion or L858R mutation in exon 21, or a known Anaplastic Lymphoma Kinase (ALK) gene rearrangement.Xx_NEWLINE_xXHematopoietic growth factor (granulocyte growth factor, erythropoiesis stimulating agent, thrombopoietin mimetic) within 28 days prior to RandomizationXx_NEWLINE_xXHematopoietic growth factors: at least 7 days since the completion of therapy with a growth factor that supports platelet, red or white cell number or functionXx_NEWLINE_xXPatients receiving first-line erlotinib, crizotinib for epidermal growth factor receptor (EGFR) mutant-positive or echinoderm microtubule associated protein like 4 (EML4)-anaplastic lymphoma receptor tyrosine kinase (ALK) positive NSCLC will be excludedXx_NEWLINE_xXKnown epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapyXx_NEWLINE_xXPatient who is growth factor or transfusion dependentXx_NEWLINE_xXPatients must be off all non-cytotoxic chemotherapies or biologic agents (e.g. azacitidine, decitabine, histone deacetylase inhibitors, tyrosine kinase inhibitors, hematopoietic growth factors, interferon, but excluding hydroxyurea and cyclophosphamide) for at least 2 weeks prior to starting induction chemotherapyXx_NEWLINE_xXPlatelets >= 50 × 10^9/L; if the bone marrow contains >= 50% plasma cells, a platelet count of >= 30 × 10^9/L is allowed (without transfusion support and without hematological growth factor support within 2 weeks of cycle 1 day 1)Xx_NEWLINE_xXPrior bevacizumab or other Vascular Endothelial Growth Factor (VEGF) or anti-angiogenic treatment (Cohort 2 only)Xx_NEWLINE_xXHematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor, 14 days for long-acting (e.g. polyethylene glycol [PEG]-filgrastim)Xx_NEWLINE_xXAt least 7 days since the completion of therapy with a hematopoietic growth agent (filgrastim, sargramostim, and erythropoietin) and 14 days for long-acting formulationsXx_NEWLINE_xXGrowth factor or cytokine support;Xx_NEWLINE_xXHemoglobin >= 8 g/dL. No transfusion or growth factor support for one week prior to labs.Xx_NEWLINE_xXPlatelet count >= 75 x 10^9/L. No transfusion or growth factor support for one week prior to labs.Xx_NEWLINE_xXPlatelet count >= 75 K/uL, unless if cytopenias are deemed to be due disease at discretion of clinical investigator; transfusions and growth factors are permissibleXx_NEWLINE_xXHematopoietic growth factors: ?14 days after the last dose of a long-acting growth factor or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occurXx_NEWLINE_xXInterleukins, interferons, and cytokines (other than hematopoietic growth factors): ?21 days after the completion of interleukins, interferons or cytokines (other than hematopoietic growth factors)Xx_NEWLINE_xXVascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-targeted or mammalian target of rapamycin (mTOR)-targeted therapies: Must not have received prior exposure to lenvatinib; May have previously progressed on an mTOR inhibitor; No more than 2 prior VEGF/VEGFR-targeted therapies (For Phase 2 only); Must not have received prior VEGF/VEGFR-targeted therapy in combination with an mTOR inhibitor (For Phase 2 only)Xx_NEWLINE_xXPatients must have normal organ and marrow function, independent of growth factor or transfusion support; patients should not receive growth factors or transfusions for at least 7 days prior to first dose of study drug, with the exception of pegylated G-CSF (pegfilgrastim) and darbepoeitin which require at least 14 days prior to screening and randomizationXx_NEWLINE_xXPrior use of growth factors =< 14 days prior to registrationXx_NEWLINE_xXPART A: Non-small cell lung cancer (NSCLC) with adenocarcinoma histology must have been previously tested for both epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangementsXx_NEWLINE_xXPatients must not have received prior therapy with topotecan, pazopanib, or related drugs such as tyrosine kinase inhibitors, vascular endothelial growth factor (VEGF) inhibitors (except bevacizumab); prior treatment with tyrosine kinase inhibitors (TKIs) that do not impact VEGF receptor (R) -1, -2, or -3, platelet-derived growth factor receptor (PDGFR) -a, -b of v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolo (cKIT) could be allowedXx_NEWLINE_xXPatients must have acceptable organ and marrow function, which should be present independent of growth factor or transfusion support for at least 7 days prior to first dose of study drug, with the exception of pegylated G-CSF (pegfilgrastim) and darbopoeitin which require a 14-day period between dosing and first dose of study drugXx_NEWLINE_xXNo prior treatment with an inhibitor of vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)Xx_NEWLINE_xXSubjects must not be receiving growth factors, except for erythropoietinXx_NEWLINE_xXPrior use of cetuximab or another epidermal growth factor receptor (EGFR) inhibitor is allowable and if used as a single agent should not be considered as a cytotoxic chemotherapy (nor should other targeted therapies be considered as a prior line of cytotoxic chemotherapy)Xx_NEWLINE_xXHemoglobin >= 9 g/dL without need for hematopoietic growth factor or transfusion support within 30 days prior to treatment initiationXx_NEWLINE_xXPrior therapy with an inhibitor of vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR) (including bevacizumab)Xx_NEWLINE_xXProgression following a single line of prior cytotoxic therapy including a platinum agent plus a standard cytotoxic partner other than a taxane (typically pemetrexed, gemcitabine or vinorelbine):\r\n* Previous treatment with targeted therapy will not count as a prior line of therapy if the patient’s tumor has the relevant molecular change (e.g., epidermal growth factor receptor [EGFR] mutation for erlotinib and echinoderm microtubule associated protein like 4 [EML4]/anaplastic lymphoma receptor tyrosine kinase [ALK] or receptor tyrosine kinase [ROS1] for crizotinib)\r\n* Previous treatment with immune-oncologic agents (such as nivolumab) will not count as a prior line of therapyXx_NEWLINE_xXNeutrophils < 1.0 x 10^9/L (neutrophil count should be > 1000 without growth factor support, unless neutropenia is caused by anti-neutrophil antibodies or other manifestation of chronic GVHD)Xx_NEWLINE_xXParticipants may not have received any prior anti-vascular endothelial growth factor (VEGF) antibody or inhibitor including but not limited to bevacizumabXx_NEWLINE_xXGrowth factors: interval >= 1 week and >= 2 weeks before study enrollment for standard and long-acting growth factors (e.g., pegfilgrastim), respectivelyXx_NEWLINE_xXPrior treatment within the past 6 months with sunitinib, sorafenib, bevacizumab or other multikinase inhibitors targeting any of the following: vascular endothelial growth factors 1–3 (VEGF1–3), FMS-like tyrosine kinase 3 (FLT3), stem cell growth factor (c-KIT), platelet-derived growth factors-alpha and -beta (PDGF-alpha,-beta), colony-stimulating factor 1 (CSF1), and the ‘RET’ receptor for glial-derived neurotrophic factorsXx_NEWLINE_xXGrowth factor(s): must not have received within 2 weeks of entry onto this studyXx_NEWLINE_xXProgression on, or intolerance of, or ineligibility for all standard therapies (including regimens containing fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and an anti-epidermal growth factor receptor [EGFR] antibody [where appropriate]); patients who are intolerant of, or ineligible for 5-FU, oxaliplatin, and/or the combination of both will be excludedXx_NEWLINE_xXPrior treatment with an investigational or marketed inhibitor of the epidermal growth factor receptor (EGFR) pathway or an Aurora Kinase inhibitorXx_NEWLINE_xXPatients with mutations in the epidermal growth factor receptor (EGFR) gene; the mutational status of all patients with adenocarcinoma and non-squamous histology will be determined prior to study entryXx_NEWLINE_xXDocumented activating epidermal growth factor receptor mutation (Del19 and/or L858R) with tumour tissues.Xx_NEWLINE_xXPrior treatment with epidermal growth factor receptor targeting small molecules or antibodies.Xx_NEWLINE_xXSubject must be chemotherapy naive (except Arm D, K, L and M). Prior use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is acceptable. For Arms D, K, and L, subjects must be non-progressors within 42 days after completion of first-line treatment with ?4 cycles of Platinum Doublet chemotherapy with or without Bevacizumab. See below for Arm MXx_NEWLINE_xXPatients who have received prior systemic therapy for their RCC with vascular endothelial growth factor (VEGF) pathway inhibitor (such as sunitinib, sorafenib, and bevacizumab) or with mammalian target of rapamycin (mTOR) inhibitors (such as sirolimus, temsirolimus, everolimus, or deforolimus)Xx_NEWLINE_xXPrior targeted therapy (anti-vascular endothelial growth factor [VEGF] agents or mammalian target of rapamycin [mTOR] inhibitors) including adjuvant therapy, and prior chemotherapy for metastatic RCC (mRCC); however, prior immunotherapy (cytokines or vaccines) is allowedXx_NEWLINE_xXUse of bevacizumab or vascular endothelial growth factor inhibitor chemotherapy within 3 months before RT or 6 months after RTXx_NEWLINE_xXPatients must have recurrent disease and may have had any number of prior relapses (including no prior relapses) on NON-anti-vascular endothelial growth factor (VEGF)(receptor [R]) containing regimens; relapse is defined as progression following initial therapy; for patients who progressed on a prior anti-VEGF(R) containing regimen including bevacizumab, only one prior relapse on an anti-VEGF(R) containing regimen is allowedXx_NEWLINE_xXSubject must have adequate bone marrow independent of growth factor support per local laboratory reference range at Screening.Xx_NEWLINE_xXPrevious treatment with anti-angiogenesis agents including thalidomide, or inhibitors of epidermoid growth factor (EGF), platelet derived growth factor (PDGF), or fibroblast growth factors (FGF) receptorsXx_NEWLINE_xXHemoglobin >= 8.0 g/dL (without transfusion or growth factor support)Xx_NEWLINE_xXPrior anti-epidermal growth factor receptor antibody therapy (e.g. panitumumab or cetuximab) or prior small molecule anti-epidermal growth factor receptor therapy (e.g. erlotinib) for adenocarcinoma of the small bowel or ampulla of VaterXx_NEWLINE_xXUse of hematopoietic growth factors within the 2 weeks prior to initiation of therapyXx_NEWLINE_xXPlatelet count >= 75 K/uL, unless if cytopenias are deemed to be due to disease at discretion of clinical investigator; transfusions and growth factors are permissibleXx_NEWLINE_xXNeutrophils >= 1.0 x 10^9/L (growth factor support is not allowed), within 14 days prior to registrationXx_NEWLINE_xXNo prior treatment with a vascular endothelial growth factor (VEGF) inhibitorXx_NEWLINE_xXParticipants may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks; subjects may not have received prior treatment affecting the vascular endothelial growth factor (VEGF) pathway in the recurrent setting, including thalidomide, bevacizumab, sunitinib, or sorafenib; in the Phase I portion of the trial, subjects may not have received prior treatment with oregovomab (OvaRex) or any other antibodies that may interfere with CA-125 measurementsXx_NEWLINE_xXFor Arm A, patients must be at first recurrence of GBM, must not have had previous anti-vascular endothelial growth factor (VEGF) therapy, and must be candidates for surgical partial or gross-total resectionXx_NEWLINE_xXPatients may have received up to two prior therapies including vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR) and programmed cell death (PD)-1/PD ligand 1 (L1) inhibitors; prior palliative radiation to metastatic lesion(s) is permitted, provided there is at least one measurable and/or evaluable lesion(s) that has not been irradiatedXx_NEWLINE_xXNeutrophil count >= 1.5 x 10^9/l anytime within the last seven days before enrollment; patients can be on myeloid or erythroid growth factors, for example filgrastimXx_NEWLINE_xXAny degree of prior treatment is allowed, including other anti-angiogenic treatments (e.g., vascular endothelial growth factor receptor 2 [VEGFR2] inhibitors or bevacizumab); patients with no prior therapy are eligible, provided they have metastatic disease that is not curable by surgeryXx_NEWLINE_xXGrowth factors within 14 days prior to screening labsXx_NEWLINE_xXNo concurrent growth factors unless vital for the patientXx_NEWLINE_xXTumors with driver mutations (epidermal growth factor receptor mutation positive or anaplastic lymphoma kinase fusion oncogene positive) should have had disease progression or been intolerant to the standard tyrosine-kinase inhibitor (TKI), and should include a second line TKI where such therapy is available and indicated.Xx_NEWLINE_xXGastric cancer (including gastric and EGJ cancers): at least 2 prior systemic regimens in adjuvant, advanced, or metastatic setting and, as appropriate, a human epidermal growth factor receptor 2 (HER2) targeted agent.Xx_NEWLINE_xXHematopoietic grow factors: It must have been at least 7 days since the completion of therapy with GCSF or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta®).Xx_NEWLINE_xXHemoglobin >= 8 g/dL (without platelet transfusion or myeloid growth factor support within two weeks of screening)Xx_NEWLINE_xXAdministration of myeloid growth factors or platelet transfusion within 14 days prior to the first dose of study treatmentXx_NEWLINE_xXSubject has received blood transfusions or hematopoietic growth factor therapy within 14 days prior to the first dose of study drug.Xx_NEWLINE_xXPrior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g. fms-related tyrosine kinase 3 [FLT3] inhibitors, other kinase inhibitors), or hematopoietic growth factors is allowedXx_NEWLINE_xXSubjects that are known to be epidermal growth factor (EGFR)-activating mutation positive must have received an EGFR inhibitor.Xx_NEWLINE_xXPatients known to be positive for activating Epidermal Growth Factor Receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocationXx_NEWLINE_xXPrevious therapy with other vascular endothelial growth factor (VEGF) or VEGFR inhibitors (other than bevacizumab) or docetaxel for the treatment of NSCLC at any timeXx_NEWLINE_xXReceived any hematopoietic growth factors within 14 days prior to screening.Xx_NEWLINE_xXPatients with known activating mutations in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma receptor tyrosine kinase (ALK) or c-ros oncogene 1, receptor tyrosine kinase (ROS-1) (this test [ROS-1] will be done only on select patients and at the discretion of treating physicians) translocation positive; the mutational status of all patients will be determined prior to study entryXx_NEWLINE_xXTumor without activating driver mutations for which there is available therapy (eg, tumor without mutations in epidermal growth factor receptor or anaplastic lymphoma).Xx_NEWLINE_xXTumor tissue available for epidermal growth factor receptor (EGFR) expression analysisXx_NEWLINE_xXPrior treatment with anti-vascular endothelial growth factor (VEGF) drugs other than bevacizumabXx_NEWLINE_xXPrior treatment with tyrosine-kinase inhibitors targeting VEGF, platelet-derived growth factor, fibroblast growth factor, tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 (TIE-2), or angiopoietin (or their receptors)Xx_NEWLINE_xXGrowth factors that support platelet or white cell number or function must not have been administered within the past 7 days; growth factors include: GCSF (filgrastim), PEG-GCSF (Neulasta), GM-CSF (sargramostim) and erythropoietinXx_NEWLINE_xXHave had prior treatment with regorafenib or any other (vascular endothelial growth factor receptor) VEGFR-targeting kinase inhibitor.Xx_NEWLINE_xXPatients with targetable mutation i.e. epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK), must have been treated with at least 1 prior tyrosine kinase inhibitor (TKI)Xx_NEWLINE_xXHematopoietic growth factors: at least 7 days must have elapsed since the completion of therapy with a growth factor; at least 14 days must have elapsed after receiving pegfilgrastimXx_NEWLINE_xXAcceptable hematologic status (without growth factor support for neutropenia or transfusion dependency):Xx_NEWLINE_xXPatients must have received at least one platinum-containing regimen for the treatment of advanced or metastatic disease (except for epidermal growth factor receptor [EGFR]-mutant patients); prior maintenance therapy is allowed and will be considered as the same line of therapy when continued without discontinuation after initiation of a treatment regimen; NSCLC with documented EGFR mutation will be eligible after progression on an EGFR-tyrosine-kinase inhibitor (TKI) alone; NSCLC with other molecular targets, such as fusion gene involving the anaplastic lymphoma kinase (ALK) gene (such as echinoderm microtubule associated protein like 4 [EML4]-ALK) or ROS proto-oncogene 1 , receptor tyrosine kinase (ROS-1), will be eligible if they have progressed on targeted agents (ALK inhibitor) and chemotherapy or are not a candidate for chemotherapyXx_NEWLINE_xXHemoglobin >= 9.0 g/dl (transfusion and/or growth factor support allowed)Xx_NEWLINE_xXThe institution’s pre-enrollment biomarker screening at a Clinical Laboratory Improvement Amendments (CLIA) certified lab documents presence of known “sensitive” mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon 19 deletion, L858) and/or EML4-anaplastic lymphoma kinase (ALK) fusion arrangement; either the primary tumor or the metastatic lymph node tissue may be used for testing of mutationsXx_NEWLINE_xXA minimum of 5 days must have elapsed since the administration of hematopoietic growth factors with short half life (filgrastim, erythropoietin), while for longer – acting hematopoietic growth factors, the minimum time elapsed is 20 daysXx_NEWLINE_xXEpidermal growth factor receptor (EGFR) mutationsXx_NEWLINE_xXReceived prior treatment with Insulin-like Growth Factor 1 Receptor (IGF-1R) inhibitors, Phosphatidylinositol 3-Kinase (PI3K) inhibitors, or other experimental agents that target PI3K, Protein Kinase B (AKT), or Mammalian Target of Rapamycin (mTOR) pathwayXx_NEWLINE_xXLUNG ADENOCARCINOMA COHORT (COHORT 3 ONLY): Patients must have had at least one prior therapy for advanced disease (platinum-containing chemotherapy or one of the approved targeted therapies [an approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for EGFR mutant tumors or crizotinib and ceritinib for anaplastic lymphoma receptor tyrosine kinase (ALK) translocated tumors]); there is no limit to the number of prior chemotherapy regimens receivedXx_NEWLINE_xXPrior treatment with epidermal growth factor receptor (EGFR)-targeted small molecules, EGFR-targeted antibodies, and/or any investigational agents for HNSCCXx_NEWLINE_xXHemoglobin >= 9.0g/dL (without need for transfusion support within 30 days; growth factor allowed)Xx_NEWLINE_xXLAPATINIB DITOSYLATE ARM: Patients must have one of the following as determined by analysis of the primary tumor or a metastatic site in a CLIA certified laboratory:\r\n* Human epidermal growth factor receptor 2 (ERBB2) mutation or\r\n* ERBB2 gene amplification by FISH (gene to chromosome ration > 2)Xx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (i.e. filgrastim, sargramostim or erythropoietin); 14 days must have elapsed if patients received poly(ethylene glycol) (PEG) formulationsXx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (i.e. filgrastim, sargramostim or erythropoietin); 14 days must have elapsed if patients received PEG formulationsXx_NEWLINE_xXPatients who have been previously treated with MET or vascular endothelial growth factor receptor (VEGFR) inhibitors (except for patients on renal cell cancer [RCC] cohort) are not eligible for the expansion cohorts but can enroll in the phase I portionXx_NEWLINE_xXPatients who have received hematopoietic growth factors (filgrastim, pegfilgrastim, or sargramostim) within 28 days of first dose of screeningXx_NEWLINE_xXFailed or were intolerant to at least one prior systemic treatment regimen with oral or IV medications and have no additional therapy options known to prolong survival with the exception of PD-1 or PD-L1 blockade therapy for subjects who will be enrolled in treatment arm A. Subjects with non-small cell lung cancer must have received at least one platinum doublet regimen. Subjects with known epidermal growth factor receptor tyrosine kinase inhibitor activating mutations or anaplastic lymphoma kinase rearrangement must have also exhausted approved targeted therapy options;Xx_NEWLINE_xXPatients who had received prior EPO treatment or other recombinant growth factors regardless of the outcome (Patient who had received prior EPO treatment or other recombinant growth factors for less than 4 weeks and not within 3 months before screening without a documented response are allowed)Xx_NEWLINE_xXAt least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chairXx_NEWLINE_xXendocrine therapy, immunotherapy, transfusion, hematopoietic factors within 14 days prior to planned first dose of study drug (Note: After completion of dose escalation, patients with AML are not required to meet these hematologic criteria, eg. transfusions and hematopoietic growth factors.)Xx_NEWLINE_xXendocrine therapy, immunotherapy, transfusion, or hematopoietic factors within 14 days prior to planned first dose of study drug (Note: Patients with AML are not required to meet these hematologic criteria, eg, transfusions and hematopoietic growth factors.),Xx_NEWLINE_xXAdequate tissue for central immunohistochemical (IHC) assay of Met receptor, and epidermal growth factor receptor (EGFR) testing if EGFR status is unknownXx_NEWLINE_xXPrior exposure to experimental treatment targeting either the hepatocyte growth factor (HGF) or Met pathwayXx_NEWLINE_xXHematopoietic grow factors: It must have been at least 7 days since the completion of therapy with GCSF or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta®).Xx_NEWLINE_xXHematologic growth factors are not allowed at screening or during the first cycle of treatmentXx_NEWLINE_xXKnown epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutated disease (molecular testing not required prior to study entry)Xx_NEWLINE_xXThere will be no limit on number of prior therapies for NSCLC; patients with previously untreated NSCLC will be eligible if they are uninterested in or ineligible for standard first line chemotherapy; patients with NSCLC known to harbor an anaplastic lymphoma kinase (ALK) rearrangement, or epidermal growth factor receptor (EGFR) mutation known to be sensitive to Food and Drug Administration (FDA) approved tyrosine kinase inhibitors (TKI), are only eligible after experiencing disease progression (during or after treatment) or intolerance to an FDA approved EGFR TKI or ALK TKI, respectivelyXx_NEWLINE_xXblood transfusion or hemopoietic factor therapyXx_NEWLINE_xXAdequate hematologic function independent of transfusion and growth factor support for at least 7 days prior to screening (with the exception of pegylated G-CSF (pegfilgrastim) and darbepoetin which require at least 14 days prior to screening), defined as:Xx_NEWLINE_xXSubject with a tumor of non-squamous histology must be tested for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement. Subject with EGFR activating mutation or ALK rearrangement must have experienced disease progression or unacceptable toxicity/intolerance after receiving at least one EGFR tyrosine kinase inhibitor or ALK inhibitor;Xx_NEWLINE_xXPrior systemically administered nitrosoureas or vascular endothelial growth factor (VEGF) targeted therapyXx_NEWLINE_xXPrevious treatment with agents targeting the insulin like growth factor (IGF) signalling pathway.Xx_NEWLINE_xXThere should be a minimum of 4 weeks from any prior chemotherapy, immunotherapy and/or radiation, with the exception of hormonal therapy for prostate and breast cancers, human epidermal growth factor receptor (HER)2-directed therapy for HER2+ breast cancer (3+ immunohistochemistry [IHC] or fluorescence in situ hybridization [FISH]+), and erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancer in the expansion cohort; there should be a minimum of 6 weeks from any prior antibody therapies, (such as ipilimumab or anti-programmed cell death [PD]1/programmed death-ligand [PDL]1)Xx_NEWLINE_xX3 months must have elapsed between any prior anti-vascular endothelial growth factor (VEGF) treatment (for example, given as a component of primary treatment) and study participation; these therapies include bevacizumab, cediranib, axitinib, sunitinib as well as other therapeutics targeting VEGFXx_NEWLINE_xXA documented somatic activating mutation in epidermal growth factor receptor (EGFR) (including but not limited to exon 19 deletion or L858R)Xx_NEWLINE_xXAt least 7 days since the completion of therapy with hematopoietic growth factorsXx_NEWLINE_xXPrior therapy targeting the epidermal growth factor receptor (EGFR) pathwayXx_NEWLINE_xXPrior treatment with any agent targeting the hepatocyte growth factor (HGF)/c-Met pathwayXx_NEWLINE_xXPrior cancer chemotherapy, bevacizumab (or other vascular endothelial growth factor [VEGF]/VEGF receptor [VEGFR]-directed agent), or an investigational agent for recurrent/progressive GBM or prior bevacizumab as part of initial therapy (prior chemotherapy or investigational agents are permitted as part of initial therapy; VEGF/VEGFR-directed agents are not permitted).Xx_NEWLINE_xXPatients with epidermal growth factor receptor (EGFR) overactivity mutations or anaplastic lymphoma kinase (ALK) rearrangements must have received tyrosine-kinase inhibitor (TKI) therapy prior to consideration for enrollment;Xx_NEWLINE_xXConcomitant use of biological agents including growth factors. Exception: 3- to 6-patient breast cancer cohort enrolled to explore the use of prophylactic growth-factor support of a 1.4 mg/m2 dose of eribulin.Xx_NEWLINE_xXRadiographic disease recurrence or progression during or after front-line platinum-based doublet chemotherapy. For patients with known epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) translocations, appropriate targeted treatment should have been used. Mutation testing is not required.Xx_NEWLINE_xXFor participants with a documented epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement, one additional line of non-cytotoxic prior treatment will be permitted provided the therapy is a targeted agent against the EGFR mutation or ALK rearrangement.Xx_NEWLINE_xXPresence of an activating EGFR (epidermal growth factor receptor) mutation or ALK (anaplastic lymphoma kinase) translocation in the tumor.Xx_NEWLINE_xXKnown presence of documented sensitizing epidermal growth factor receptor (EGFR) activating mutation or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation (screening following local standards, but strongly encouraged in non-squamous histology)Xx_NEWLINE_xXUnknown epidermal growth factor receptor (EGFR)mutation status or previously known EGFR mutated status in patients with adenocarcinoma.Xx_NEWLINE_xXPatients with any known epidermal growth factor receptor (EGFR) mutation and/or anaplastic lymphoma receptor tyrosine kinase (ALK) translocationXx_NEWLINE_xXPrior history with BIBF 1120 or any other vascular endothelial growth factor (VEGF)/VEGF receptor (R) inhibitorXx_NEWLINE_xXPrior treatment with an investigational or approved agent for the purpose of inhibiting human epidermal growth factor receptor (HER) family members. This includes, but is not limited to, cetuximab, panitumumab, erlotinib, gefitinib, and lapatinibXx_NEWLINE_xXPrior treatment with an epidermal growth factor receptor (EGFR) inhibitor is allowed if it was administered as part of definitive therapy for locally advanced disease and completed/terminated >/= 3 months before study enrollmentXx_NEWLINE_xXPrior exposure to agents targeting either the Hepatocyte Growth Factor (HGF) or MET pathwayXx_NEWLINE_xXPatients who received prior phosphoinositide-3-kinase (PI3K) inhibitor or anti-receptor tyrosine-protein kinase erbB-3 (ERBB3 or HER3) antibody treatment, including bi-specific antibodies with HER3 as one of the targets (patients with prior exposure to pertuzumab or epidermal growth factor receptor (EGFR)-targeted agents are eligible)Xx_NEWLINE_xXPatients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer are also excluded from this portion of the studyXx_NEWLINE_xXANC > 1500/mm³, platelets > 100,000/mm³, Hgb > 9 g/dL. Values must be obtained without need for myeloid growth factor or platelet transfusion support within 14 days, however, erythrocyte growth factor is allowed as per published ASCO guidelines.Xx_NEWLINE_xXSubjects must have a solid tumor type likely to over-express Epidermal Growth Factor Receptor (EGFR) (Phase 1)Xx_NEWLINE_xXRefractory disease defined as: \r\n* Prior treatment with fluoropyrimidine, oxaliplatin, irinotecan, and anti-epidermal growth factor receptor (EGFR) therapy if v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wildtype for colorectal adenocarcinoma and\r\n* Prior treatment with fluoropyrimidine and oxaliplatin for small bowel adenocarcinomaXx_NEWLINE_xXPatient must be refractory to or intolerant of prior therapy with a fluoropyrimidine, oxaliplatin, irinotecan, and/or anti-angiogenic therapy; patients with v-Ki-ras2 Kirsten rat sarcoma (K-RAS) wild type tumors must have received an epidermal growth factor receptor (EGFR) inhibitor such as cetuximab or panitumumabXx_NEWLINE_xXTumors with clear cell histology: subject must have progressed after at least one anti-vascular endothelial growth factor receptor (anti-VEGFR) therapyXx_NEWLINE_xXPrior treatment with investigational drugs that target the human growth factor (HGF) or MET pathwayXx_NEWLINE_xXGrowth factors that support platelet or white cell number or function must not have been administered within 7 days of blood draw documenting hematopoietic function (ANC, Platelets) eligibility. .Xx_NEWLINE_xXANC: 1000/ul (no short acting hematopoietic growth factors within 7 7 days of blood draw documenting eligibility and no long-acting hematopoietic growth factors within 14 days of blood draw documenting eligibility)Xx_NEWLINE_xXPrevious systemic anti-vascular endothelial growth factor (VEGF) or any prior systemic anti-cancer therapy, including prior treatment with systemic agents such as regorafenib, ramucirumab, pazopanib, or experimental agents such as brivanib.Xx_NEWLINE_xXPrior treatment with any agent that targets vascular endothelial growth factor (VEGF) or VEGF receptors (VEGFR) (licensed or investigational including sorafenib), except bevacizumabXx_NEWLINE_xXPatients who have had prior anti-epidermal growth factor receptor (EGFR) antibody therapy and who have not responded to this treatment will be excluded; however, patients who have responded to prior anti-EGFR therapy are eligibleXx_NEWLINE_xXPatient has known contraindication to PARP inhibitors or vascular endothelial growth factor (VEGF) inhibitors.Xx_NEWLINE_xXPrior treatment with any anti-HER3 (Human Epidermal growth factor Receptor 3) treatmentXx_NEWLINE_xXPatients must have metastatic disease which has progressed on or within 6 months of stopping treatment with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors; previous therapy with bevacizumab, interleukin 2, or interferon alpha is also permittedXx_NEWLINE_xXNSCLC with documented epidermal growth factor receptor (EGFR) mutation associated with response to EGFR inhibitors or documented fusion gene involving anaplastic lymphoma kinase (ALK) geneXx_NEWLINE_xXResults of endothelial growth factor receptor (EGFR)-activating mutation testingXx_NEWLINE_xXEpidermal growth factor receptor (EGFR)-mutation-positive disease according to local laboratory testingXx_NEWLINE_xXPrior treatment with epidermal growth factor receptor (EGFR)-targeted small moleculesXx_NEWLINE_xXPatients with either previous vascular endothelial growth factor (VEGF) inhibition based treatment or previous vorinostat based treatment are eligible; however, patients who received both VEGF and histone deacetylase (HDAC) inhibition simultaneously are ineligibleXx_NEWLINE_xXThe participant has a history of treatment with other agents targeting the Insulin-like or Epidermal Growth factor receptors.Xx_NEWLINE_xXReceived prior therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)Xx_NEWLINE_xXPatients who have received prior therapy with any anti-vascular endothelial growth factor (VEGF) drug, including bevacizumabXx_NEWLINE_xXPrevious therapy with other vascular endothelial growth factor (VEGF) inhibitors (other than bevacizumab) or pemetrexed for treatment of NSCLCXx_NEWLINE_xXGrowth factors: Must be off growth factor(s) > 1 week prior to study entry (filgrastim [GCSF], sargramostim [GM CSF], erythropoietin).Xx_NEWLINE_xXHuman epidermal growth factor receptor 2 (HER-2)/neu negative (phase II)Xx_NEWLINE_xXPrior use of any monoclonal antibodies directly targeting the epidermal growth factor receptor (EGFr). Subjects who have received prior tyrosine kinase inhibitors such as gefitinib or erlotinib are eligible.Xx_NEWLINE_xXHemoglobin ? 10 g/dL, independent of transfusion or growth factor supportXx_NEWLINE_xXHemoglobin > 8 mg/dL without need for hematopoetic growth factor or transfusion supportXx_NEWLINE_xXProphylactic use of hematopoietic growth factors within 1 week prior to starting trial treatmentXx_NEWLINE_xXAdministration of myeloid growth factors or platelet transfusion within 14 days prior to the first dose of study treatmentXx_NEWLINE_xXAt least 7 days since the completion of therapy with a growth factor and at least 14 days since pegfilgrastim (Neulasta) administrationXx_NEWLINE_xXSubject is receiving anticoagulant, pro-coagulant or antithrombotic, antiplatelet agents, and/or PLT specific growth factors within 10 days prior to randomizationXx_NEWLINE_xXSubject is receiving anticoagulant, pro-coagulant or antithrombotic, antiplatelet agents, and/or PLT specific growth factors within 10 days prior to randomizationXx_NEWLINE_xXTreatment plan that includes any neoadjuvant or adjuvant therapy (either in the context of standard treatment or a clinical trial and including chemotherapy, treatments targeting the human epidermal growth factor receptor protein 2 [HER2]), hormonal therapy, or radiation; patients can receive any/all of these therapy components while on study in any combinationXx_NEWLINE_xXSecond malignancies are allowed as long as the disease does not require active treatment with concomitant systemic cytotoxic chemotherapy, investigational or biologic therapy (e.g., anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] or human epidermal growth factor receptor 2 [HER2] monoclonal antibodies); hormone-related therapies (e.g., gonadotrophin releasing hormone (LHRH) agonists, tamoxifen, etc.) are allowedXx_NEWLINE_xXNo pituitary diseases or growthXx_NEWLINE_xXGrowth factor/cytokine support;Xx_NEWLINE_xXGrowth factor(s): Must not have received any hematopoetic growth factors within 7 days of study entry.Xx_NEWLINE_xXHuman epidermal growth factor receptor- 2 (HER- 2) negativity will be based on the current American Society of Clinical Oncology (ASCO)-College of American Pathologists (CAP) guidelines for HER testingXx_NEWLINE_xXNo prior treatment for Stage IV non-squamous or squamous NSCLC. Participant known to have a sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) fusion oncogene are excluded from the studyXx_NEWLINE_xXCompleted adjuvant taxane-based chemotherapy as single agents or in combination with platins or human epidermal growth factor receptor 2 (HER-2) directed therapyXx_NEWLINE_xXPlatelets >= 20,000/ul without growth factor or transfusional supportXx_NEWLINE_xXPatients must have a diagnosis of colorectal or lung cancer and be planning to receive one of the following human epidermal growth factor receptor (HER1)/epidermal growth factor receptor (EGFR) inhibitor therapies listed below for at least 6 weeks:\r\n* Cetuximab 400 mg/m^2 loading dose, 250 mg/m^2 weekly\r\n* Cetuximab 500 mg/m^2 every 2 weeks\r\n* Panitumumab 6 mg/kg every 2 weeks\r\n* Erlotinib 100-150 mg daily\r\n* Other HER1/EGFR inhibitor therapies, schedules, or doses of the above listed agents are not allowed\r\n* NOTE: concurrent chemotherapy and other anti-cancer therapies (such as carboplatin, paclitaxel, and bevacizumab) are allowed EXCEPT for the following chemotherapeutic agents which are known to cause skin rash that could interfere with EGFRI-induced skin toxicity assessment: gemcitabine, capecitabine, and topical fluorouracil (Efudex, Fluoroplex, Carac)Xx_NEWLINE_xXSubject is currently on anti-EGFR (human epidermal growth factor receptor) therapy, such as Iressa (gefitinib) or Erbitux (cetuximab, C225)Xx_NEWLINE_xXPlatelets >= 20,000/ul without growth factor or transfusional supportXx_NEWLINE_xXTreatment with amifostine or palifermin (keratinocyte growth factor) during radiotherapyXx_NEWLINE_xXHave histologic diagnosis of human epidermal growth factor receptor 2 (HER2) positive (+) breast carcinomaXx_NEWLINE_xXAny patient requiring chronic maintenance of white blood cell counts or granulocyte counts through the use of growth factor support (e.g. Neulasta, Neupogen)Xx_NEWLINE_xXHemoglobin ? 10 g/dL without need for hematopoietic growth factor or transfusion supportXx_NEWLINE_xXPatient must NOT have human epidermal growth factor-2 positive (HER2+) metastatic diseaseXx_NEWLINE_xXImpaired renal function defined as epidermal growth factor receptor (eGFR) < 50 mL/min/1.73m2Xx_NEWLINE_xXParticipants who have already received anti-vascular endothelial growth factor (VEGF) or experimental anti-angiogenic therapy for glioblastomaXx_NEWLINE_xXPatients with human epidermal growth factor-2 positive (HER2+) metastatic tumors are NOT eligible.Xx_NEWLINE_xXPatient must NOT be planning to receive everolimus nor human epidermal growth factor receptor 2 (HER2) directed therapy in addition to endocrine therapy.Xx_NEWLINE_xXParticipants must have histologically or cytologically confirmed human epidermal growth factor receptor 2 (HER2) negative invasive breast adenocarcinomaXx_NEWLINE_xXSubjects with myelodysplastic syndrome who have not been treated previously with 5-azacytidine or decitabine are eligible, regardless of International Prognostic Scoring System risk score; subjects may have received transfusion support, growth factor support, or lenalidomide as previous therapy; however, they shall not have received growth factor support or lenalidomide within 4 weeks of study enrollmentXx_NEWLINE_xXHistologic diagnosis of triple negative or human epidermal growth factor receptor 2 (HER2) amplified breast cancer, clinical stage T1-4, N0-3, M0/1 receiving preoperative systemic therapy and planned surgeryXx_NEWLINE_xXPatient must not have received bevacizumab or other anti-vascular endothelial growth factor (VEGF) inhibitor in the last 3 monthsXx_NEWLINE_xXPatient must not have received any growth factors =< 7 days of entry onto this studyXx_NEWLINE_xXHistorical confirmation that the tumor harbors an epidermal growth factor receptor (EGFR) mutation known to be associated with EGFR tyrosine kinase inhibitor (TKI) sensitivity (including G719X, exon 19 deletion, L858R, L861Q)Xx_NEWLINE_xXPrior chemotherapy, monoclonal antibody or immunotherapy (eg, tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all AEs have either returned to baseline or resolved to Grade 0 or 1Xx_NEWLINE_xXAntiangiogenic therapy, specifically vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) inhibitors, can interfere with wound healing and therefore will only be allowed if the agent has been discontinued for at least 14 days prior to day 1; group C patients must be naive to therapies which target mitogen-activated protein kinase (MAPK)Xx_NEWLINE_xXAt least 1 but no more than 2 prior systemic anti vascular endothelial growth factor (anti-VEGF) treatmentsXx_NEWLINE_xXPrior treatment with any tyrosine kinase inhibitors, anti vascular endothelial growth factor (VEGF) angiogenesis inhibitors, non VEGF targeted angiogenesis inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.Xx_NEWLINE_xXParticipants with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic alternations should have PD on prior US-FDA approved therapy for these aberrations.Xx_NEWLINE_xXTwo or more prior vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR)-targeted therapies or any ongoing treatment for RR-DTC other than TSH-suppressive thyroid hormone therapy.Xx_NEWLINE_xXFor phase II only: Patients who received cetuximab or another inhibitor of epidermal growth factor receptor are excluded from the phase II of the trial, except if cetuximab was given as part of a primary treatment approach, with no progressive disease for at least 4 months following the end of prior cetuximab treatment.Xx_NEWLINE_xX